5'-Carboxy Adenosine

5'-Carboxy Adenosine

SCHEMBL2117314

Nc1ncnc2c1ncn2C1OC(C(=O)O)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHCY P23526 10/20 1.00
TMEM97 Q5BJF2 2/20 1.00
HIF1A Q16665 1/20 1.00
SIGMAR1 Q99720 1/20 1.00
ADORA2B P29275 4/20 0.82
HSP90B1 P14625 3/20 0.82
ADORA2A P29274 3/20 0.82
ADORA3 P0DMS8 5/20 0.77
ADORA1 P30542 2/20 0.75
TSHR P16473 1/20 0.75
LMNA P02545 1/20 0.75
THRB P10828 1/20 0.75
BLM P54132 1/20 0.75
KMT2A Q03164 1/20 0.75
HSP90AA1 P07900 1/20 0.75
RXFP1 Q9HBX9 1/20 0.71
HRH1 P35367 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5'-Carboxy Adenosine SCHEMBL29376409 1.00 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
5'-Carboxy Adenosine SCHEMBL8981282 1.00 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
5'-Carboxy Adenosine SCHEMBL3815016 1.00 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
5'-Carboxy Adenosine SCHEMBL2117257 1.00 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
5'-Carboxy Adenosine SCHEMBL27863662 0.95 AHCY (0.91) AHCYTMEM97HIF1ASIGMAR1ADORA2B
SCHEMBL10883314 0.90 AHCY (0.82) AHCYTMEM97HIF1ASIGMAR1ADORA2B
SCHEMBL13889874 0.90 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
SCHEMBL22354804 0.90 AHCY (1.00) AHCYTMEM97HIF1ASIGMAR1ADORA2B
SCHEMBL19189542 0.89 AHCY (0.80) AHCYTMEM97HIF1ASIGMAR1ADORA2B
SCHEMBL19190163 0.89 AHCY (0.80) AHCYTMEM97HIF1ASIGMAR1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4403042-A2 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2024-07-24 EP disclosed
EP-3229612-B1 USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2024-06-26 EP disclosed
US-11185100-B2 Methods for modulating taste receptors MARS, INCORPORATED (US) 2021-11-30 US disclosed
EP-3229610-B1 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2021-06-09 EP disclosed
US-20190021380-A1 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2019-01-24 US disclosed
US-20180355369-A1 Method for Increasing Plant Stress Tolerance and Seed Dormancy THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2018-12-13 US disclosed
US-20180255813-A1 METHODS FOR MODULATING TASTE RECEPTORS MARS, INCORPORATED (US) 2018-09-13 US disclosed
US-20180168208-A1 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2018-06-21 US disclosed
EP-2482072-B1 A PHOTOLUMINESCENT PROBE UNIV TARTU (EE) 2016-07-06 EP disclosed
US-20140057284-A1 PHOTOLUMINESCENT MOLECULAR COMPLEX AND METHOD FOR DETERMINING OF THE CONCENTRATION OF SAID MOLECULAR COMPLEX UNIVERSITY OF TARTU (EE) 2014-02-27 US disclosed
EP-2482072-A1 A photoluminescent probe University of Tartu (EE) 2012-08-01 EP disclosed
US-8158376-B2 Bisubstrate fluorescent probe binding to protein kinases UNIVERSITY OF TARTU (EE) 2012-04-17 US disclosed
US-20100233743-A1 BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES UNIVERSITY OF TARTU (EE) 2010-09-16 US disclosed
EP-2057279-A2 BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES University of Tartu (EE) 2009-05-13 EP disclosed
WO-2008019696-A2 BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES UNIVERSITY OF TARTU (EE) 2008-02-21 WO disclosed
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed
US-6534651-B2 Substituted isoindolinone derivatives INOTEK PHARMACEUTICALS CORP. 2003-03-18 US disclosed
US-6534651-B2 Substituted isoindolinone derivatives INOTEK PHARMACEUTICALS CORP. 2003-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233743-A1 BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES ADK, PRKCH, DMPK AHCY 1747/4885TMEM97 2390/4885HIF1A 2475/4885
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP AHCY 62/4885TMEM97 4737/4885HIF1A 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.